Media

Psyched Wellness Announces Del Mahabadi to Join as International Marketing Manager

Posted: May 05, 2022

Psyched Wellness Provides Update on Annual General and Special Meeting

Posted: May 03, 2022

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Posted: Apr. 26, 2022

Psyched Wellness Announces Share Purchase by Chief Executive Officer, Jeffrey Stevens

Posted: Apr. 19, 2022

Psyched Wellness to Participate in Upcoming Investor Conferences in April 2022

Posted: Apr. 12, 2022

Psyched Wellness Unveils New Product Name and Visual Identity Elements

Posted: Mar. 30, 2022

Psyched Wellness and the National Research Council of Canada Announce Preliminary Data from Studies of Neuroprotective Properties of AME-1

Posted: Mar. 24, 2022

Psyched Wellness GRAS Dossier Approved by Panel of Experts, Providing Green Light to Market Products in the United States

Posted: Mar. 08, 2022

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1

Posted: Feb. 15, 2022

Psyched Wellness Announces Additional Positive Results From The 14-Day Oral Toxicity Study Of AME-1

Posted: Feb. 03, 2022

Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares to Release Industry-First Amanita Muscaria Tincture

Posted: Feb. 01, 2022

Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada

Posted: Jan. 26, 2022

Psyched Wellness Announces Vantage Hemp Co. as Contract Manufacturing Organization Partner to Bring AME-1-derived Products to Market

Posted: Jan. 18, 2022

Psyched Wellness Announces Path to Market for AME-1 Derived Products in the USA

Posted: Dec. 16, 2021

Psyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive AME-1 Product Launch

Posted: Dec. 14, 2021

Psyched Wellness Announces Completion of Its 90 Day Oral Toxicity Study

Posted: Dec. 06, 2021

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Posted: Dec. 01, 2021

Psyched Wellness to Present at H.C. Wainwright 2nd Annual Psychedelics Conference, 2021

Posted: Nov. 30, 2021

Psyched Wellness Appoints Chief Commercial Officer to Lead Sales and Marketing of AME-1 and Launch CPG Products

Posted: Nov. 23, 2021

Psyched Wellness to Present at Grizzle Psychedelics Con on Monday, November 22, 2021

Posted: Nov. 17, 2021

Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada

Posted: Nov. 03, 2021

Psyched Wellness Announces Participation in Microdose's Wonderland: Miami on November 8-9, 2021

Posted: Nov. 01, 2021

Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1

Posted: Oct. 07, 2021

Psyched Wellness Announces Inclusion in AdvisorShares Psychedelics Exchange Traded Fund (ETF)

Posted: Sep. 22, 2021

Psyched Wellness Initiates a Clinical Sleep Study on Humans for a Structure/Function Claim for AME-1

Posted: Sep. 21, 2021

Psyched Wellness Announces Participation in the H.C. Wainwright 23rd Annual Global Investment Conference

Posted: Sep. 10, 2021

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

Posted: Sep. 08, 2021

Psyched Wellness Submits Applications for Four Further Provisional Patents Surrounding Its Work on the AME-1

Posted: Aug. 17, 2021

Psyched Wellness Enters Into a Service Agreement With CannaLabs to Begin Stability Tests on AME-1

Posted: Jul. 26, 2021

Psyched Wellness Announces Filing of Amended and Restated MD&A

Posted: Jul. 22, 2021

Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia

Posted: Jul. 22, 2021

Amanda Galbraith, Principal at Navigator Joins the Board of Psyched Wellness

Posted: Jul. 07, 2021

Psyched Wellness Receives Positive Results From Its 14 Day Oral Toxicity Preclinical Study

Posted: Jul. 06, 2021

Psyched Wellness Announces Matthew Singh Joins Team as CPG and Branding Consultant

Posted: Jun. 30, 2021

Psyched Wellness Commences Next Pre-Clinical Study on AME-1

Posted: Jun. 28, 2021

Psyched Wellness Ltd. to Present at H.C. Wainwright Conference on June 17, 2021

Posted: Jun. 10, 2021

Psyched Wellness Hires Ad Agency, dacs Marketing to Build the Branding and Marketing Strategy for AME-1

Posted: Jun. 03, 2021

Psyched Wellness to Present at the Psychedelic Investment Series on Monday, May 31, 2021

Posted: May 12, 2021

Psyched Wellness Hires the National Research Council of Canada to Test AME-1

Posted: May 11, 2021

Psyched Wellness Signs Supply Agreement for Amanita Muscaria

Posted: May 04, 2021

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

Posted: Apr. 27, 2021

Psyched Wellness Receives DTC Eligibility

Posted: Apr. 14, 2021

Psyched Wellness Initiates Study on AME-1 Extract for Gut Health

Posted: Mar. 30, 2021

Psyched Wellness Submits a Provisional Patent Application for AME-1

Posted: Mar. 17, 2021

Psyched Wellness Announces Changes to the Board of Directors

Posted: Mar. 15, 2021

Psyched Wellness Closes $6,603,000 Bought Deal Private Placement

Posted: Feb. 17, 2021

Psyched Wellness Provides Update on Antioxidant and Anti-Inflammatory Study of Muscimol

Posted: Feb. 04, 2021

Psyched Wellness to Participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference

Posted: Feb. 02, 2021

Psyched Wellness Included in First Psychedelic Exchange Traded Fund

Posted: Jan. 26, 2021

Re-Release Psyched Wellness Upsizes Previously Announced Bought Deal Offering

Posted: Jan. 25, 2021

Psyched Wellness to Present at Inaugural KCSA Psychedelics Investor Conference

Posted: Jan. 25, 2021

Psyched Wellness Upsizes Previously Announced Bought Deal Offering

Posted: Jan. 22, 2021

Psyched Wellness Announces C$3M Bought Deal Private Placement Led by Canaccord Genuity

Posted: Jan. 21, 2021

Psyched Wellness Announces New OTCQB Ticker: PSYCF

Posted: Jan. 19, 2021

Psyched Wellness Completes Initial Data Review to Determine Clinical Path for Muscimol

Posted: Jan. 14, 2021

Psyched Wellness Commences Antioxidant and Anti-Inflammatory Study on Muscimol

Posted: Jan. 06, 2021

Psyched Wellness Has Commenced Research on Muscimol for Various Ailments

Posted: Dec. 28, 2020

Psyched Wellness Commences Pre-Clinical Trials of Amanita Muscaria

Posted: Dec. 23, 2020

Psyched Wellness Successfully Completes Extraction of a Legal Psychedelic Mushroom

Posted: Dec. 15, 2020

Psyched Wellness Successfully Completes Writing the Final Extraction Protocol, the Assembly of Safety & Efficacy Narratives, and Writing the Safety Data Sheet (SDS) For Its First Product

Posted: Dec. 10, 2020

Psyched Wellness Advisor Kevin Feeney Releases Book on Amanita Muscaria

Posted: Dec. 09, 2020

Psyched Wellness LTD. Adds Aaron Slater to the Advisory Board

Posted: Dec. 08, 2020

Psyched Wellness Announces Positive Toxicology Assessment and Provides Path to Market for a Legal Psychedelic Mushroom Product

Posted: Dec. 07, 2020

Psyched Wellness Announces Successful Up-Listing to the OTCQB Venture Market

Posted: Dec. 02, 2020

Psyched Wellness LTD. Adds Kevin Feeney to the Advisory Board

Posted: Nov. 25, 2020

Psyched Wellness LTD. Announces Insider Buying and Option Grant to Professor Nutt

Posted: Nov. 18, 2020

Psyched Wellness LTD. Adds Professor David Nutt to the Board of Directors

Posted: Nov. 16, 2020

Psyched Wellness LTD. Applied to Up-List to the OTCQB and DTC Eligibility

Posted: Nov. 12, 2020

Psyched Wellness LTD. Advisor, Professor David Nutt to Speak at PsyTech Conference

Posted: Oct. 27, 2020

Psyched Wellness LTD. Adds Scientific Advisor and Grants Stock Options

Posted: Oct. 26, 2020

Psyched Wellness LTD. To Commence Trading on the CSE on October 22, 2020

Posted: Oct. 21, 2020

Psyched Wellness Announces Closing of Final Tranche of Non-Brokered Private Placement

Posted: Jul. 31, 2020

Duncan Park Announces Name Change to Psyched Wellness LTD.

Posted: Jul. 13, 2020

Duncan Park Holdings Corporation Announces Results of Annual and Special Meeting

Posted: Jul. 02, 2020

Duncan Park Holdings Corporation Announces Closing of Second Tranche of Non-Brokered Private Placement

Posted: Jun. 01, 2020

Duncan Park Holdings Corporation Announces Closing of First Tranche of Non-Brokered Private Placement

Posted: May 25, 2020

Duncan Park Holdings Corporation Announces Non-Brokered Private Placement of Common Shares

Posted: May 11, 2020

Duncan Park Holdings Corporation Announces the Appointment of Christopher Hazelton to the Board of Directors

Posted: Mar. 09, 2020

Duncan Park Holdings Corporation Appoints a New Chief Financial Officer

Posted: Jan. 27, 2020